Available evidence shows the benefits of bisphosphonate treatment outweigh the risk of atypical fractures, according to a position statement from the International Osteoporosis Foundation.
A review by researchers, on behalf of the foundation, found atypical fractures from bisphosphonate use were rare.
It follows concerns of a possible link between the two.
The authors said: “The risk versus benefit ratio is clear.
“We estimate that for every 10,000 high-risk patients undergoing bisphosphonate treatment, approximately 100 hip fractures and 750 fractures at other sites are prevented, whereas only three to six atypical fractures could be expected.”